Australia markets closed

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.1400+0.1400 (+3.50%)
As of 04:00PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.38M
Enterprise value -2.60M
Trailing P/E 2.01
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.49
Price/book (mrq)0.65
Enterprise value/revenue -1.02
Enterprise value/EBITDA 0.58

Trading information

Stock price history

Beta (5Y monthly) 2.67
52-week change 3-9.01%
S&P500 52-week change 321.23%
52-week high 35.9700
52-week low 32.5500
50-day moving average 34.0810
200-day moving average 33.8790

Share statistics

Avg vol (3-month) 35.92k
Avg vol (10-day) 34.41k
Shares outstanding 51.54M
Implied shares outstanding 61.54M
Float 81.25M
% held by insiders 119.05%
% held by institutions 11.10%
Shares short (28 Mar 2024) 41.65k
Short ratio (28 Mar 2024) 40.24
Short % of float (28 Mar 2024) 40.11%
Short % of shares outstanding (28 Mar 2024) 40.11%
Shares short (prior month 29 Feb 2024) 48.66k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 325 June 2019
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 315 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -162.78%
Operating margin (ttm)-186.87%

Management effectiveness

Return on assets (ttm)-22.29%
Return on equity (ttm)-35.27%

Income statement

Revenue (ttm)2.54M
Revenue per share (ttm)1.66
Quarterly revenue growth (yoy)38.00%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-4.13M
Diluted EPS (ttm)-2.7100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.98M
Total cash per share (mrq)5.83
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)11.84
Book value per share (mrq)6.36

Cash flow statement

Operating cash flow (ttm)-4.11M
Levered free cash flow (ttm)-2.85M